Lung Cancer, Melanoma, or Bladder Cancer Not Responding to Keytruda or Opdivo?

Check If You Qualify

Clinical trial in Adelaide testing new approach when immunotherapy stops working.

✅ Diagnosed with NSCLC, melanoma, bladder/kidney cancer, or select GI cancers

✅ Currently on or recently stopped Keytruda (pembrolizumab) or Opdivo (nivolumab)

✅ Cancer is stable or progressing according to your doctor

✅ Able to manage light daily activities


👍 Travel, meals, and accommodation fully covered.

What This Study Tests

If standard cancer treatments haven’t worked for you, this study is testing whether a blood-filtering device can provide another path forward when immunotherapy (Keytruda® or Opdivo®) is not enough.


The trial runs for 12 months and includes:

  • A screening period (up to 28 days)
  • 5-day treatment period with blood filtration
  • 8 weekly follow-up visits
  • Follow-up visits at 6 and 12 months

Locations: Adelaide, Sydney, and Gold Coast research centers.

All travel, accommodation, and meal expenses reimbursed.

Who Can Participate?

You may not qualify if you

  • Have cancer that has spread to the brain or the lining around the brain
  • Have certain immune system conditions, autoimmune disorders requiring strong medications in the past year, or are being treated for non-infectious lung inflammation
  • Have tested positive for HIV, hepatitis B, or hepatitis C
  • Cannot take full blood-thinning treatments during the Hemopurifier treatment
  • Are currently pregnant, planning pregnancy, or breastfeeding
  • Have had an allergic reaction to heparin or a serious blood reaction called heparin-induced thrombocytopenia
  • Would not be willing to receive a blood transfusion if needed
  • Have had a solid organ transplant (such as kidney, liver, heart, or lung)
  • Are currently in another clinical trial

You may qualify if you are

  • Adult aged 18 and above who are diagnosed with one of these cancers: 
  • Non-small cell lung cancer
  • Melanoma
  • Bladder or urinary tract cancer
  • Kidney cancer
  • Colorectal cancer (MSI-H or dMMR)
  • Stomach or gastr-oesophageal junction cancer
  • Oesophageal cancer
  • Head and neck cancer
  • Cervical cancer
  • Mesothelioma
  • Currently receiving treatment with Keytruda® (pembrolizumab) or Opdivo® (nivolumab), with recent scans showing the cancer is stable or growing.
  • Able to carry out normal activities with little or some limitations (such as doing light work or household tasks).
  • Willing to use effective birth control during the study and for about 4 months after (if applicable).
  • Able to attend the required study visits, including: 
  • A screening period (up to 28 days)
  • Hemopurifier® treatment sessions before the next scheduled dose of immunotherapy one to three treatments (4 hour long treatments) over a 1 week period.
  • A safety follow-up visit 28 days later, and follow-up visits for up to 1 year.

Why Participate?

  • Receive the investigational Hemopurifier® treatment together with your current immunotherapy (Keytruda® or Opdivo®), all at no additional costs to your regular care.
  • Join one of three study cohorts, where you’ll receive 3 Hemopurifier® sessions in a one week period before your next scheduled dose of immunotherapy.
  • Be reimbursed for travel and lodging.
  • Help test a new approach that may strengthen how the immune system fights cancer.
  • Contribute to research that could improve treatment options and outcomes for future cancer patients.

Meet the Lead Researcher

Professor Michael Brown

Professor Michael Brown is a senior Medical Oncologist and Director of the Cancer Clinical Trials Unit at the Royal Adelaide Hospital. After completing his medical degree at the University of Sydney and fellowship at the Royal Australasian College of Physicians, he obtained his doctorate from the University of Adelaide...

Prof Brown is dual-qualified in clinical immunology and medical oncology, with advanced research training in cancer immunotherapy. A Clinical Professor of Medical Oncology at the University of Adelaide, he is widely recognised for his leadership in cancer research and innovation in clinical trial design.

With over 20 years of clinical oncology experience, Prof Brown focuses on early-phase immunotherapy trials for melanoma and lung cancer. He has authored over 140 publications in leading scientific journals and heads a research laboratory at the Centre for Cancer Biology, aimed at delivering rapid access to advanced cancer therapies.

Since 2006, he has led the Cancer Clinical Trials Unit at RAH, overseeing more than 40 active trials. He is also a Board Member of the Australian Genomic Cancer Medicine Program, a project delivering clinical trials to Australians affected by rare cancers.

Study Details and Location

MEET THE RESEARCH CENTER

Royal Adelaide Hospital - Cancer Clinical Trials Unit

Research Site:

Royal Adelaide Hospital - Cancer Clinical Trials Unit

Location:

Royal Adelaide Hospital, Port Road, Adelaide SA 5000

Lead Researcher:

Professor Michael Brown

Ethics Committee:

This study has been reviewed and approved by the Royal Adelaide Hospital Ethics Committee

The Cancer Clinical Trials Unit (CCTU) is located at the Royal Adelaide Hospital, offering patients access to advanced treatments and high-quality care. As part of the Central Adelaide Local Health Network, the unit is a leading centre for oncology research and healthcare innovation.


Led by experienced oncologists and supported by a dedicated team of highly qualified staff, the CCTU manages more than 40 active clinical trials. The research unit was purpose-built with state-of-the-art facilities to conduct clinical trials, providing patients with access to emerging therapies for a range of cancer types.

We Have You Covered

Qualified Health Professionals
IRB Approved
Trained Staff

Qualified Health Professionals

Ethics Approved

Trained Staff

Qualified health professionals will monitor your health as it relates to the study.

This trial has been reviewed and approved by an independent ethics committee. 

All research staff that are running this trial have been trained in GCP, which assures that the rights, safety, and well-being of research subjects are protected and respected.

Data Encrypted
HIPPA Compliant

National Privacy Standards

Encrypted Data

We follow all established national privacy standards used in all doctors' offices, hospitals and other businesses where personal medical information is stored.

All data you provide us is encrypted and stored safely and securely in accordance with security and privacy rules.

Your Rights

Informed Consent Before Participation

Withdraw At Any Time

Strictly Confidential

Your records relating to this study and any other information received will be kept strictly confidential, except as required by the law.

If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.

You will receive a detailed outline of all details of the study, including treatment, risks and procedures, and given the chance to ask questions to study staff, before you decide whether to participate.

Ready to make a

difference?

Is this study not for you?

Join our new trial email list to be notified of new trials that could be a fit for you.

© 2024 Trialfacts. All Rights Reserved. | (415) 704-1575 USA | (07) 3054 7094 AUS support@trialfacts.com | Privacy Policy